Drugs / Virus specific CTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02779439 | Jan 2013 → Dec 2017 | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | University of Sydney | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Virus specific CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02779439 ↗ |
| Modality | Cell therapy | “Off-the-shelf, third-party virus-specific T cells (VSTs) appear promising” PMID 29296867 ↗ Nov 2017 |